About Asthmatx
Asthmatx is a Healthcare company based in Sunnyvale (United States) founded in 2003, and was acquired by Boston Scientific in September 2010. Bronchial thermoplasty devices are developed for adult asthma treatment. Asthmatx has raised $50 million across 1 funding round from investors including Boston Scientific and Olympus. Its focus areas include Life Sciences, Pulmonology, Medical Devices and Therapeutic Devices. Its legal entity is ASTHMATX INC. Its competitors include Nuvaira, RejuvenAir and D R Burton; 2 of its 3 listed competitors have raised funding.
Company details
Asthmatx is a medical device company, focuses on developing and commercializing a therapeutic treatment for asthma in the United States. The company has developed a technology that is designed to deliver controlled thermal radiofrequency energy to the airways of adult patients to reduce the mass of airway smooth muscle in a procedure called Bronchial Thermoplasty. Asthmatx offers an interventional medical device, called the Alair System, for the bronchoscopic treatment of patients with moderate to severe asthma. The Alair Bronchial Thermoplasty System is indicated for the treatment of severe persistent asthma in patients 18 years and older whose asthma is not well-controlled with inhaled corticosteroids and long-acting beta-agonist medicines. Patients are treated in multiple sessions, each targeting a different section of the airways.
- Headquarters Sunnyvale, United States
- Stage Acquired
- SectorsHealthcare
- Website asthmatx.com
- Social X
- Acquired by Boston Scientific (Sep 2010)
- Legal Name Asthmatx Inc.
- Total Equity Funding$50M (USD)
in 1 rounds
- Latest Funding Round$50M (USD), Series D
May 2007
- InvestorsBoston Scientific
& 1 more
- Acquired byBoston Scientific
(Sep 2010)
Funding Insights of Asthmatx
Asthmatx has successfully raised a total of $50M through 1 strategic funding round. The most recent funding activity was a Series D round of $50 million completed in May 2007. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $50M
- Total Rounds 1
- Last Round Series D — $50M
- First Round $50M
(May 2007)
- Investors Count 1
All 1 funding rounds of Asthmatx with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2007 | $50M | Series D | – | – |
2 investors in total: 2 institutional.
Investors in Asthmatx
Asthmatx has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Boston Scientific and Olympus.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Manufacturer of imaging and surgical products | 1919 | olympus-global.com | Tokyo, Japan | |
Wide range of medical devices | 1979 | bostonscientific.com | Marlborough, United States |
Investor details for Asthmatx
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Asthmatx
3 dated milestones of Asthmatx across 7 years, from founding to its latest funding, stage changes and deals.
- Founded Asthmatx is founded.
- Funding First funding round of $50.0M.
- Exit Acquired by Boston Scientific.
Competitors of Asthmatx
Asthmatx has 3 listed competitors in our database, 2 of them funded. They include Nuvaira, RejuvenAir and D R Burton.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| nuvaira.com | 2008 | Minneapolis, United States | $233.15M | 57 | A catheter-based system for COPD treatment is developed and provided. | |
| rejuvenair.com | 2006 | Lexington, United States | $171.11M | Cryosurgical device for chronic bronchitis and COPD treatment is developed. | ||
| drburtonhpi.com | 2015 | Raleigh, United States | Provides comprehensive products for positive pressure therapy in lung disease patients. |
Detailed competitors of Asthmatx
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Pulmonology
3 companies that operate in the same segment as Asthmatx (Pulmonology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of novel protein-based therapeutics using machine learning and biological engineering | 2018 | Somerville, Massachusetts, United States | USD 693 M | 329 | ||
Portable oxygen concentrators are supplied for respiratory therapy needs. | 2001 | Goleta, California, United States | USD 51.65 M | USD 348.67 M | 766 | |
Robotic microsurgical systems for endoscopy are developed. | 2007 | Redwood City, California, United States | USD 733.62 M | 91 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Asthmatx
Complete news archive for Asthmatx
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Asthmatx
Asthmatx was founded in 2003 and raised its 1st funding round 4 years after it was founded.
Asthmatx is headquartered in Sunnyvale, United States. It is registered at Sunnyvale, California, United States.
Asthmatx is a funded company, having raised a total of $50M across 1 funding round to date. The company's 1st funding round was a Series D of $50M, raised on May 2007.
Asthmatx is a medical device company, focuses on developing and commercializing a therapeutic treatment for asthma in the United States. The company has developed a technology that is designed to deliver controlled thermal radiofrequency energy to the airways of adult patients to reduce the mass of airway smooth muscle in a procedure called Bronchial Thermoplasty. Asthmatx offers an interventional medical device, called the Alair System, for the bronchoscopic treatment of patients with moderate to severe asthma. The Alair Bronchial Thermoplasty System is indicated for the treatment of severe persistent asthma in patients 18 years and older whose asthma is not well-controlled with inhaled corticosteroids and long-acting beta-agonist medicines. Patients are treated in multiple sessions, each targeting a different section of the airways.
Asthmatx's top competitors include Nuvaira, RejuvenAir and D R Burton.
Asthmatx has 2 investors. Key investors include Boston Scientific, and Olympus.
Asthmatx operates through Asthmatx Inc..
Yes. Asthmatx was acquired by Boston Scientific in September 2010.